Please ensure Javascript is enabled for purposes of website accessibility
David Jagielski

David Jagielski

TMFdjagielski

David Jagielski is a designated accountant and has spent 10+ years working in finance for small and large businesses in many different sectors. He has been writing for The Fool since 2017. When he's not out hunting for cheap stocks or writing articles, odds are he's writing macros in Excel or reading history books.

Recent articles

A couple meeting with an advisor.

2 Scorching-Hot Deals to Buy in the Nasdaq Bear Market

Investors should be careful not to overlook these promising long-term investments.


A family adding coins to a piggy bank.

2 High-Yielding Dividend Stocks to Power Up Your Passive Income

These stocks pay generous dividends, and their payouts have been rising for decades.


Frustrated people looking at a laptop.

Are Investors Repeating Mistakes They Made in 2020?

For rational long-term investors, now could be the time to buy.


people working in a lab

Why Pfizer Looks Better Than Moderna as a Long-Term Buy

In a post-COVID world, there are fewer question marks about Pfizer than there are about Moderna.


Business people looking at a tablet.

Moderna Just Made a $700,000 Mistake

But it's not the stock that investors should be worried about.

Businessman with a chart looking at his computer.

2 Cheap Growth Stocks Near Their 52-Week Lows to Buy and Forget

Buying these stocks on the dip could result in big returns for investors.


Businessman checking his phone.

2 Growth Stocks at All-Time Lows That Could Be the Ultimate Contrarian Buys

Investors shouldn't count these stocks out just yet.


Person receiving a vaccine.

This Is the Most Important Number From Novavax's Q1 Earnings

Novavax is doing well now, but what about the future?


A couple reviewing a document at home.

Could This Stock's 9.9% Dividend Yield Be a Golden Ticket?

Can you rely on Omega Healthcare's extremely high payout?


Two business people meeting over coffee.

This Growth Stock Is Raising Guidance Despite Multiple Headwinds

The company is coming off a strong quarter and expects that pattern to continue.

People working in a greenhouse.

Did IIPR's Q1 Results Calm Investors' Fears?

The stock was hit by a scathing short-seller report last month.


A couple using a laptop and reviewing documents.

2 Promising Growth Stocks That Are Down 70% From Their Highs

These are stocks that could make for great long-term investments.


A couple making financial decisions with the help of a laptop and calculator.

Got $10,000? These 3 Growth Stocks Also Pay Dividends

These stocks can make the most of your money.


A couple reviewing a statement.

Worried About Inflation? Buy These 2 High-Yielding Dividend Stocks

These stocks are worth hanging onto beyond just this year.


A couple looking at a tablet during breakfast.

This Dividend Stock Has Been Increasing Its Payouts for 75 Straight Periods

Healthcare Services is not a Dividend King but it has an impressive streak going.

people working in a lab

Is Regeneron In Trouble After Sales Declined 40% In a Single Quarter?

The pharmaceutical company's COVID-19 treatment wasn't the only product suffering this past quarter.


Person testing cannabis in a lab.

Down 80% From Its High, Can Tilray Stock Spark Again?

Is Tilray the best cannabis stock to hold if marijuana legalization happens in the U.S.?


A couple counting money.

Got $5,000? Buy and Hold These 3 Dividend Growth Stocks for the Long Haul

If you invest in these stocks, it's likely your dividend income will increase over the years.


People in an office cheering.

2 Red-Hot Stocks That Soared More Than 60% in April

Could these be the next big meme stocks?


A group of scientists looking at a report.

Is Moderna Wasting a Golden Opportunity?

Moderna will likely need to make a move sooner or later.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.